{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:34:07Z","timestamp":1761057247294},"reference-count":13,"publisher":"Wiley","issue":"s64","license":[{"start":{"date-parts":[[2002,1,2]],"date-time":"2002-01-02T00:00:00Z","timestamp":1009929600000},"content-version":"vor","delay-in-days":397,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Allergy"],"published-print":{"date-parts":[[2000,12]]},"abstract":"<jats:p>Symptoms of allergic rhinitis include sneezing; itching of the eyes, nose, and throat; nasal obstruction; and rhinorrhoea; they may be seasonal or perennial, depending on the causative allergen. The major symptom of perennial allergic rhinitis is nasal obstruction. Sneezing and rhinorrhoea are often present, but are less troublesome than in seasonal allergic rhinitis. Symptom relief is a priority in allergic rhinitis because patients have a severely impaired quality of life. The nasal vascular system is complex. Histamine acts on postcapillary venules during both the immediate and late phase of reactivity and causes plasma extravasation. Other inflammatory mediators can also induce this reaction. Thus, histamine antagonists that also have some additional antiallergic properties have advantages in the treatment of allergic rhinitis. Mizolastine is a second\u2010generation antihistamine that has been shown, in experimental studies, to possess 5\u2010lipoxygenase inhibitory properties in addition to its H<jats:sub>1<\/jats:sub>\u2010receptor antagonistic activity. In the treatment of seasonal allergic rhinitis, mizolastine 10\u2003mg\/day has been shown to be effective in reducing nasal and ocular symptoms. It has been shown to be significantly more effective than placebo with a greater percentage of responders. Another study has shown that symptoms of seasonal allergic rhinitis in mizolastine\u2010treated patients were reduced more significantly than in cetirizine\u2010treated patients on the second and third days of treatment. In perennial allergic rhinitis, mizolastine significantly improved symptoms of nasal obstruction compared with placebo and also significantly reduced nasal membrane colour, nasal secretions, and mucosal swelling as shown by rhinoscopy. These effects were maintained over a 5\u2010month treatment period. Mizolastine has also been shown to be at least as effective as loratadine, and in one trial even superior in the treatment of perennial allergic rhinitis.<\/jats:p>","DOI":"10.1034\/j.1398-9995.2000.00805.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T01:44:31Z","timestamp":1047347071000},"page":"34-39","source":"Crossref","is-referenced-by-count":11,"title":["Clinical advantages of dual activity in allergic rhinitis"],"prefix":"10.1111","volume":"55","author":[{"given":"F.","family":"Horak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,1,2]]},"reference":[{"key":"e_1_2_9_2_2","first-page":"47","article-title":"Prospective epidemiological longitudinal study in allergic diseases","volume":"8","author":"Temmel AFP","year":"1998","journal-title":"Otorhinolaryngol Nova"},{"key":"e_1_2_9_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(97)70127-1"},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2222.2000.00668.x"},{"key":"e_1_2_9_5_2","first-page":"201","volume-title":"Essential allergy","author":"Mygind N","year":"1996"},{"key":"e_1_2_9_6_2","first-page":"1","article-title":"International Consensus Report on Diagnosis and Management of Rhinitis","volume":"49","author":"International Rhinitis Management Working Group","year":"1994","journal-title":"Allergy"},{"key":"e_1_2_9_7_2","first-page":"155","article-title":"Inhibitory effect of mizolastine on 5\u2010lipoxygenase","volume":"26","author":"Sudo K","year":"1998","journal-title":"Jpn Pharmacol Ther"},{"key":"e_1_2_9_8_2","doi-asserted-by":"crossref","unstructured":"MichelL Murrieta\u2010AguttesM Jean\u2010LouisF LevyD&DubertretL.Humoral and cellular responses to histamine and pollen allergen in a skin chamber model: effect of mizolastine.Ann Allergy Asthma Immunol2000;85:64\u201369.","DOI":"10.1016\/S1081-1206(10)62436-2"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/030006059802600603"},{"key":"e_1_2_9_10_2","first-page":"P531","article-title":"Seasonal allergic rhinitis (SAR): a pooling of mizolastine trials","volume":"51","author":"Levy D","year":"1996","journal-title":"Allergy"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62672-5"},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1998.tb03798.x"},{"key":"e_1_2_9_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/030006059902700603"},{"key":"e_1_2_9_14_2","first-page":"152","article-title":"Placebo controlled study of mizolastine 10\u2003mg and loratadine 10\u2003mg once daily in perennial allergic rhinitis (PAR)","volume":"54","author":"Fr\u00e8che CH","year":"1999","journal-title":"Allergy"}],"container-title":["Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1398-9995.2000.00805.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1034\/j.1398-9995.2000.00805.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T08:46:18Z","timestamp":1695804378000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1034\/j.1398-9995.2000.00805.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,12]]},"references-count":13,"journal-issue":{"issue":"s64","published-print":{"date-parts":[[2000,12]]}},"alternative-id":["10.1034\/j.1398-9995.2000.00805.x"],"URL":"https:\/\/doi.org\/10.1034\/j.1398-9995.2000.00805.x","archive":["Portico"],"relation":{},"ISSN":["0105-4538","1398-9995"],"issn-type":[{"value":"0105-4538","type":"print"},{"value":"1398-9995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,12]]}}}